POS0516 Applicability of the phase 3 Trial DAISY (Detecting effectiveness of Anifrolumab In SYstemic Sclerosis) inclusion criteria to the general SSc population – a study from the EUSTAR cohort

Kaye, E., Osborne, T., Thornton, L. et al. (4 more authors) (2025) POS0516 Applicability of the phase 3 Trial DAISY (Detecting effectiveness of Anifrolumab In SYstemic Sclerosis) inclusion criteria to the general SSc population – a study from the EUSTAR cohort. In: Annals of the Rheumatic Diseases. EULAR 2025: European Congress of Rheumatology, 11-14 Jun 2025, Barcelona, Spain.

Metadata

Item Type: Proceedings Paper
Authors/Creators:
Copyright, Publisher and Additional Information:

POS0516 Applicability of the phase 3 Trial DAISY (Detecting effectiveness of Anifrolumab In SYstemic Sclerosis) inclusion criteria to the general SSc population – a study from the EUSTAR cohort
Keywords: Clinical Trial; Real-world evidence; Observational studies/ registry
Dates:
  • Published (online): 18 June 2025
  • Published: 18 June 2025
Institution: The University of Leeds
Academic Units: The University of Leeds > Faculty of Medicine and Health (Leeds) > School of Medicine (Leeds)
Depositing User: Symplectic Publications
Date Deposited: 18 Jul 2025 12:14
Last Modified: 18 Jul 2025 12:14
Status: Published
Identification Number: 10.1016/j.ard.2025.05.898
Related URLs:
Open Archives Initiative ID (OAI ID):

Download not available

A full text copy of this item is not currently available from White Rose Research Online

Export

Statistics


CORE (COnnecting REpositories)